Anti-complement effects of lactoferrin-derived peptides

FEMS Immunology and Medical Microbiology

Volumn 41, Issue 2, 2004, Pages 141-148

  Samuelsen, Ørjan ^a,b   Haukland, Hanne H ^a,b   Ulvatne, Hilde ^a   Vorland, Lars H ^a,b,c  

^a UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

Author keywords

Antimicrobial peptides; Complement inhibition; Lactoferricin; Lactoferrin

Indexed keywords

ANTIINFECTIVE AGENT; LACTOFERRIN; LACTOFERRIN B; LACTOFERRIN H; PEPTIDE; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ANTIMICROBIAL ACTIVITY; ARTICLE; CATTLE; CONCENTRATION RESPONSE; DRUG ACTIVATION; DRUG EFFECT; DRUG INHIBITION; ESCHERICHIA COLI; HUMAN; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL;

AMINO ACID SEQUENCE; ANIMALS; ANTI-BACTERIAL AGENTS; CATTLE; COMPLEMENT PATHWAY, ALTERNATIVE; COMPLEMENT PATHWAY, CLASSICAL; COMPLEMENT SYSTEM PROTEINS; ESCHERICHIA COLI; FEMALE; HEMOLYSIS; HUMANS; LACTOFERRIN; MALE; MICROBIAL SENSITIVITY TESTS; MOLECULAR SEQUENCE DATA; PEPTIDE FRAGMENTS;

EID: 2442540559     PISSN: 09288244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.femsim.2004.02.006     Document Type: Article

References (36)

1. Zasloff M. Antimicrobial peptides of multicellular organisms. Nature. 415:2002;389-395
2. Yang D., Chertov O., Oppenheim J.J. The role of mammalian antimicrobial peptides and proteins in awakening of innate host defenses and adaptive immunity. Cell Mol. Life Sci. 58:2001;978-989
3. Panyutich A.V., Szold O., Poon P.H., Tseng Y., Ganz T. Identification of defensin binding to C1 complement. FEBS Lett. 19:1994;169-173
4. Prohaszka Z., Nemet K., Csermely P., Hudecz F., Mezo G., Fust G. Defensins purified from human granulocytes bind C1q and activate the classical complement pathway like the transmembrane glycoprotein Gp41 of HIV-1. Mol. Immunol. 34:1997;809-816
5. van den Berg R.H., Faber-Krol M.C., van Wetering S., Hiemstra P.S., Daha M.R. Inhibition of activation of the classical pathway of complement by human neutrophil defensins. Blood. 92:1998;3898-3903
6. van den Berg R.H., Faber-Krol M.C., van Wetering S., Hiemstra P.S., Daha M.R. Inhibition of activation of the classical pathway of complement by human neutrophil defensins. Blood. 92:1998;3898-3903
7. Vorland L.H. Lactoferrin: a multifunctional glycoprotein. APMIS. 107:1999;971-981
8. Morgan O.S., Bankay J., Quash G.A. The effect of lactoferrin, an iron-binding protein on complement activity. West Indian Med. J. 24:1975;46-54
9. Veerhuis R., Kijlstra A. Inhibition of hemolytic complement activity by lactoferrin in tears. Exp. Eye Res. 34:1982;257-265
10. Kijlstra A., Jeurissen S.H. Modulation of classical C3 convertase of complement by tear lactoferrin. Immunology. 47:1982;263-270
11. Kievits F., Kijlstra A. Inhibition of C3 deposition on solid-phase bound immune complexes by lactoferrin. Immunology. 54:1985;449-456
12. Tomita M., Bellamy W., Takase M., Yamauchi K., Wakabayashi H., Kawase K. Potent antibacterial peptides generated by pepsin digestion of bovine lactoferrin. J. Dairy Sci. 74:1991;4137-4142
13. Bellamy W., Takase M., Yamauchi K., Wakabayashi H., Kawase K., Tomita M. Identification of the bactericidal domain of lactoferrin. Biochim. Biophys. Acta. 1121:1992;130-136
14. Bellamy W., Takase M., Wakabayashi H., Kawase K., Tomita M. Antibacterial spectrum of lactoferricin b, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J. Appl. Bacteriol. 73:1992;472-479
15. Bellamy W., Takase M., Wakabayashi H., Kawase K., Tomita M. Antibacterial spectrum of lactoferricin b, a potent bactericidal peptide derived from the N-terminal region of bovine lactoferrin. J. Appl. Bacteriol. 73:1992;472-479
16. Andersen J.H., Osbakk S.A., Vorland L.H., Traavik T., Gutteberg T.J. Lactoferrin and cyclic lactoferricin inhibit the entry of human cytomegalovirus into human fibroblasts. Antiviral Res. 51:2001;141-149
17. Andersen J.H., Jenssen H., Gutteberg T.J. Lactoferrin and lactoferricin inhibit herpes simplex 1 and 2 infection and exhibit synergy when combined with acyclovir. Antiviral Res. 58:2003;209-215
18. Turchany J.M., Aley S.B., Gillin F.D. Giardicidal activity of lactoferrin and N-terminal peptides. Infect Immun. 63:1995;4550-4552
19. Isamida T., Tanaka T., Omata Y., Yamauchi K., Shimazaki K., Saito A. Protective effect of lactoferricin against toxoplasma gondii infection in mice. J. Vet. Med. Sci. 60:1998;241-244
20. Bellamy W., Wakabayashi H., Takase M., Kawase K., Shimamura S., Tomita M. Killing of Candida Albicans by lactoferricin B, a potent antimicrobial peptide derived from the N-terminal region of bovine lactoferrin. Med. Microbiol. Immunol. (Berl). 182:1993;97-105
21. Haversen L.A., Baltzer L., Dolphin G., Hanson L.A., Mattsby-Baltzer I. Anti-inflammatory activities of human lactoferrin in acute dextran sulphate-induced colitis in mice. Scand. J. Immunol. 57:2003;2-10
22. Britigan B.E., Lewis T.S., Waldschmidt M., McCormick M.L., Krieg A.M. Lactoferrin binds CpG-containing oligonucleotides and inhibits their immunostimulatory effects on human B cells. J. Immunol. 167:2001;2921-2928
23. Haversen L.A., Engberg I., Baltzer L., Dolphin G., Hanson L.A., Mattsby-Baltzer I. Human lactoferrin and peptides derived from a surface-exposed helical region reduce experimental Escherichia coli urinary tract infection in mice. Infect. Immun. 68:2000;5816-5823
24. Mattsby-Baltzer I., Roseanu A., Motas C., Elverfors J., Engberg I., Hanson L.A. Lactoferrin or a fragment thereof inhibits the endotoxin-induced interleukin-6 response in human monocytic cells. Pediatr. Res. 40:1996;257-262
25. Davidson L.A., Lonnerdal B. Fe-saturation and proteolysis of human lactoferrin: effect on brush-border receptor-mediated uptake of Fe and Mn. Am. J. Physiol. 257:1989;G930-G934
26. Vorland L.H., Ulvatne H., Rekdal O., Svendsen J.S. Initial binding sites of antimicrobial peptides in Staphylococcus aureus and Escherichia coli. Scand. J. Infect. Dis. 31:1999;467-473
27. Roos A., Nauta A.J., Broers D., Faber-Krol M.C., Trouw L.A., Drijfhout J.W., Daha M.R. Specific inhibition of the classical complement pathway by C1q-binding peptides. J. Immunol. 167:2001;7052-7059
28. Andersson M., Boman A., Boman H.G. Ascaris nematodes from pig and human make three antibacterial peptides: isolation of cecropin P1 and two ASABF peptides. Cell Mol. Life Sci. 60:2003;599-606
29. Zasloff M. Magainins, a class of antimicrobial peptides from xenopus skin: isolation, characterization of two active forms, and partial CDNA sequence of a precursor. Proc. Natl. Acad. Sci. USA. 84:1987;5449-5453
30. Walport M.J. Complement. First of two parts. N. Engl. J. Med. 344:2001;1058-1066
31. Walport M.J. Complement. Second of two parts. N. Engl. J. Med. 344:2001;1140-1144
32. Fujita T. Evolution of the lectin-complement pathway and its role in innate immunity. Nat. Rev. Immunol. 2:2002;346-353
33. Elass-Rochard E., Roseanu A., Legrand D., Trif M., Salmon V., Motas C., Montreuil J., Spik G. Lactoferrin-lipopolysaccharide interaction: involvement of the 28-34 loop region of human lactoferrin in the high-affinity binding to Escherichia coli 055B5 lipopolysaccharide. Biochem. J. 312:1995;839-845
34. Baker E.N., Anderson B.F., Baker H.M., Day C.L., Haridas M., Norris G.E., Rumball S.V., Smith C.A., Thomas D.H. Three-dimensional structure of lactoferrin in various functional states. Adv. Exp. Med. Biol. 357:1994;1-12
35. Yeaman M.R., Gank K.D., Bayer A.S., Brass E.P. Synthetic peptides that exert antimicrobial activities in whole blood and blood-derived matrices. Antimicrob. Agents Chemother. 46:2002;3883-3891
36. Oh J.E., Hong S.Y., Lee K.H. Structure-activity relationship study: short antimicrobial peptides. J. Pept. Res. 53:1999;41-46